ArticleFrontiers in oncology2026
Adult-onset primary hemophagocytic syndrome with concurrent Epstein-Barr virus infection: a case report with literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the clinical and laboratory features, phenotypic characteristics, associated genes, and treatment strategies for adult primary hemophagocytic lymphohistiocytosis (HLH). Methods: The clinical characteristics and underlying causes of an adult primary HLH patient were analyzed according to the HLH-2004 diagnostic criteria. Gene sequences of HLH-related genes (UNC13D, PRF1, STX11, STXBP2, RAB27A, etc.) in the patient and his family were amplified using polymerase chain reaction (PCR) and subsequently analyzed. Results: The confirmed case involved a 42-year-old male patient presenting with recurrent fever, pancytopenia, hepatosplenomegaly, lymphadenopathy, elevated serum ferritin (600 ng/mL), significantly decreased NK cell activity (3.57%), and elevated soluble CD25 (2777 U/mL), all of which led to a diagnosis of HLH according to the HLH-2004 diagnostic criteria. The patient's serum EBV-DNA was elevated and was associated with cryptococcal infection of the central nervous system. After antiviral and antifungal treatments, EBV-DNA levels normalized, cerebrospinal fluid examination returned to normal, and primary HLH with an UNC13D gene mutation was confirmed by gene sequencing. Conclusions: While primary HLH is more prevalent in infants and young children, it can also occur in adolescents and adults, often being misdiagnosed as secondary HLH due to concurrent EBV infection. Molecular genetic alterations are crucial for distinguishing primary from secondary HLH, and HLH-related gene screening remains essential in adult patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.